Department of Neonatology, Xinhua Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Department of Neonatology, Shanghai Children's Medical Center Shanghai Jiao Tong University School of Medicine, Shanghai, China.
BMC Pediatr. 2024 Sep 28;24(1):616. doi: 10.1186/s12887-024-05096-0.
With the release of the coronavirus disease 2019 (COVID-19) pandemic in late 2022 in China, the number of people infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) roared, including neonatal cases. However, there were few studies on neonatal COVID-19, especially multi-center case reports. This study aimed to explore clinical characteristics and short-term outcomes of neonatal COVID-19 in China.
We reviewed 187 cases of neonatal COVID-19 between December 11, 2022, and January 12, 2023. The diagnosis was assessed by symptoms, laboratory tests, X-ray manifestations, and diagnosis code. Clinical characteristics and outcomes were evaluated.
In 187 neonatal cases with COVID-19, 84 (44.9%) had severe SARS-CoV-2 infection. Most patients had confirmed exposure to SARS-CoV-2. Fever and respiratory symptoms were common (75.4% and 71.7%, respectively). Severe patients were more likely to have high alanine transaminase (ALT) (> 40U/L) (11.9% vs. 3.9%) and high N-terminal pro-brain natriuretic peptide (NT-proBNP) (> 2000pg/mL) (38.0% vs. 19.6%), compared with nonsevere ones (P < 0.05). None of the patients received COVID-19-specific medical interventions. A few severe patients received corticosteroids (1.1%), and immunoglobulin (0.5%), respectively. All patients were discharged home after the medical care with a median length of stay (LOS) of four days and none of them met the criteria of multisystem inflammatory syndrome in neonates (MIS-N).
After the release of the epidemic situation of COVID-19 in late 2022 in China, more neonatal cases with severe COVID-19 had high ALT and NT-proBNP level. Few specific medical interventions were given, and the outcome was satisfying.
2022 年末中国新冠肺炎（COVID-19）大流行爆发，感染严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）的人数剧增，包括新生儿病例。然而，关于新生儿 COVID-19 的研究较少，尤其是多中心病例报告。本研究旨在探讨中国新生儿 COVID-19 的临床特征和短期结局。
我们回顾了 2022 年 12 月 11 日至 2023 年 1 月 12 日期间 187 例新生儿 COVID-19 病例。通过症状、实验室检查、X 线表现和诊断代码评估诊断。评估了临床特征和结局。
在 187 例 COVID-19 新生儿病例中，84 例（44.9%）为严重 SARS-CoV-2 感染。大多数患者有明确的 SARS-CoV-2 接触史。发热和呼吸道症状常见（分别为 75.4%和 71.7%）。严重病例更可能出现高丙氨酸转氨酶（ALT）（>40U/L）（11.9%比 3.9%）和高 N 末端脑利钠肽前体（NT-proBNP）（>2000pg/mL）（38.0%比 19.6%），与非严重病例相比差异有统计学意义（P<0.05）。没有患者接受 COVID-19 特异性医疗干预。少数严重患者分别接受了皮质类固醇（1.1%）和免疫球蛋白（0.5%）治疗。所有患者在接受医疗护理后出院回家，中位住院时间（LOS）为 4 天，均不符合新生儿多系统炎症综合征（MIS-N）标准。
2022 年末中国 COVID-19 疫情爆发后，更多重症 COVID-19 新生儿的 ALT 和 NT-proBNP 水平升高。很少给予特定的医疗干预，结局令人满意。
